British Patient Capital — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)inTom McCarthy(Co-founder)in
Co-investorsAndera PartnersCanaan PartnersOxford Science EnterprisesPfizer Venture InvestmentsEarlybird Venture CapitalPfizer Ventures
Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.
BiotechDigital HealthHealthtechMedical Devices
Moin Saleem(Co-founder & Chief Scientific Advisor)in
Co-investorsSofinnova PartnersForbionGilde Healthcare
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.